Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab
PaperCitations, authors & open-access status
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 164 citations, 2017 year and closed oa status.
164
Citations
2017
Year
closed
OA Status